BHC
EW icon

Bowen Hanes & Co’s Edwards Lifesciences EW Stock Holding History

Bowen Hanes & Co’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-355,145
Closed -$33.5M – 144
2023
Q2 		$33.5M Buy
+355,145
New +$30.9M 1.07% 45
2023
Q1 		– Sell
-4,550
Closed -$339K – 145
2022
Q4 		$339K Sell
4,550
-24,820
-85% -$1.91M 0.01% 128
2022
Q3 		$2.43M Sell
29,370
-260
-0.9% -$25K 0.09% 84
2022
Q2 		$2.82M Sell
29,630
-255,290
-90% -$26.4M 0.1% 84
2022
Q1 		$33.5M Buy
284,920
+47,390
+20% +$5.32M 1% 46
2021
Q4 		$30.8M Buy
+237,530
New +$27.7M 0.87% 48

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Bowen Hanes & Co's EW Position: Q3 2023 in Review

Bowen Hanes & Co sold out of Edwards Lifesciences (EW) in Q3 2023, closing a stake of 355,145 shares — an estimated $33.5M sold.

Bowen Hanes & Co first reported a position in EW in Q4 2021 and held it in 6 quarters. The position peaked at $33.5M in Q1 2022. 1,220 funds tracked by Wall St. Rank hold EW as of Q3 2023.

  • Bowen Hanes & Co reported no remaining Edwards Lifesciences position as of Q3 2023 after selling out during the quarter.
  • Bowen Hanes & Co sold 355,145 Edwards Lifesciences shares in Q3 2023, an estimated $33.5M.
  • Bowen Hanes & Co first reported a position in Edwards Lifesciences in Q4 2021 and held it in 6 quarters.
  • Bowen Hanes & Co's Edwards Lifesciences position peaked at $33.5M in Q1 2022.
  • 1,220 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2023.

Based on Bowen Hanes & Co's 13F filing for Q3 2023, filed 13 Nov 2023.